Could CAR T-Cells halt progressive MS? early trial launches

NCT ID NCT07139743

Recruiting now Disease control Sponsor: Autolus Limited Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new treatment called obe-cel, a type of cell therapy (CAR T-cell), for people with progressive multiple sclerosis (MS) that hasn't improved with standard treatments. The main goal is to see if it's safe, but researchers will also look for any signs it might slow the disease. Only 18 adults aged 18 to 60 will receive a single infusion of obe-cel after a short course of chemotherapy, and they will be followed for two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: obe-cel (a CAR T-cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for people with progressive multiple sclerosis that hasn't responded to other therapies.
What could go wrong: This is a very early, small Phase 1 trial with only 18 people, so it's mainly checking safety. The treatment may not work, and there are risks from the chemotherapy given beforehand and potential side effects from the cell therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROGRESSIVE MULTIPLE SCLEROSIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Addenbrooke's Hospital
RECRUITING

Cambridge, United Kingdom
Hospital Universitari i Politecnic La Fe de Valencia
RECRUITING

Valencia, Spain
Hospital Universitario Vall d'Hebron - PPDS
ACTIVE_NOT_RECRUITING

Barcelona, Spain
Royal Hallamshire Hospital
RECRUITING

Sheffield, United Kingdom
Stanford University
NOT_YET_RECRUITING

Redwood City, California, 94063, United States
The National Hospital for Neurology & Neurosurgery
RECRUITING

London, United Kingdom
Western General Hospital Edinburgh - PPDSE Edinburgh
RECRUITING

Edinburgh, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.